In Vitro and In Vivo Evaluation of Two Hydroxychloroquine Tablet Formulations: HPLC Assay Development

Abstract

The relative in vitro and in vivo evaluation of two hydroxychloroquine (HCQ) products was conducted. In vitro studies involved assay, content uniformity and dissolution test, and a two-way crossover fashion were used for in vivo studies. Blood samples were collected at appropriate intervals and HCQ levels were measured using a validated reversed-phase high-performance liquid chromatography (HPLC) method. The drug and the internal standard, chloroquine (CQ), were extracted from blood with diethyl ether, separated and dried under nitrogen gas. Residues were reconstituted in the mobile phase and analyzed at 340 nm on a mu-bondapack C18 (250 x 4.6 mm) HPLC column with acetonitrile:methanol:KH2PO4 (10:10:80) mixture containing 0.01 triethylamine. The standard curve was linear within 50-1,500 ng/mL HCQ (R-2 = 0.9996), relative errors were 1.6 to 5, and the CV ranged from 7 to 15.4. The resolution factor and RSD were 1.62 and 0.35 and in vitro data of both products met the USP requirements. The 90 confidence intervals for the ratios of the AUC(0-96), C-max and T-max and their corresponding logarithmically transformed values of generic product over those of Plaquenil (R) were within the acceptable limit of 0.80-1.20 and 0.80-1.25, respectively. Therefore, the generic HCQ was bioequivalent to the innovator formulation.